Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686

Abstract

We thank Dr. Dhatariya (1) for his interest in our study that assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) and related events in the canagliflozin type 2 diabetes clinical trial program (2). Our analysis of DKA and related events was based on a standard collection of adverse event reports from investigators and included verbatim terms that map to the specific terms of diabetic ketoacidosis, ketoacidosis, metabolic acidosis, and acidosis from the Medical Dictionary …